14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $227.75 $262.51 Friday, 3rd May 2024 UTHR stock ended at $262.40. This is 1.65% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 2.57% from a day low at $255.93 to a day high of $262.51.
90 days $208.62 $262.51
52 weeks $204.44 $262.51

Historical United Therapeutics Corporation prices

Date Open High Low Close Volume
Jan 17, 2024 $217.84 $222.30 $217.16 $222.25 321 467
Jan 16, 2024 $218.48 $220.90 $216.96 $218.72 358 084
Jan 12, 2024 $221.42 $225.11 $218.68 $219.05 212 694
Jan 11, 2024 $220.00 $220.44 $215.89 $220.30 458 291
Jan 10, 2024 $224.63 $224.63 $220.25 $221.66 380 010
Jan 09, 2024 $229.59 $229.96 $222.05 $224.36 329 581
Jan 08, 2024 $228.01 $231.06 $224.02 $231.04 277 289
Jan 05, 2024 $229.17 $230.85 $226.48 $229.40 255 404
Jan 04, 2024 $228.09 $230.50 $226.49 $230.11 360 751
Jan 03, 2024 $227.85 $228.68 $226.27 $228.18 349 960
Jan 02, 2024 $219.72 $228.54 $219.31 $227.35 413 663
Dec 29, 2023 $219.02 $220.70 $217.57 $219.89 257 943
Dec 28, 2023 $215.02 $220.89 $214.43 $219.24 386 947
Dec 27, 2023 $215.30 $218.07 $214.11 $214.88 387 708
Dec 26, 2023 $219.99 $220.19 $215.47 $216.27 422 507
Dec 22, 2023 $219.45 $223.72 $218.79 $218.93 423 480
Dec 21, 2023 $225.92 $226.80 $217.63 $218.27 610 769
Dec 20, 2023 $240.27 $240.70 $225.15 $225.51 1 087 298
Dec 19, 2023 $246.01 $246.43 $240.17 $240.26 424 769
Dec 18, 2023 $247.86 $247.96 $243.75 $246.40 364 056
Dec 15, 2023 $253.31 $255.50 $245.58 $246.45 570 435
Dec 14, 2023 $257.10 $258.31 $252.61 $254.09 384 521
Dec 13, 2023 $251.02 $257.27 $250.55 $256.94 313 834
Dec 12, 2023 $246.17 $252.08 $244.75 $251.70 298 047
Dec 11, 2023 $242.00 $244.98 $241.00 $244.86 198 561
Click to get the best stock tips daily for free!

About United Therapeutics Corporation

United Therapeutics United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a... UTHR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT